Lesion clearance rate, itch reduction doubled with TYK2/JAK1 inhibitor brepocitinib ...

An investigative synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum, was associated with greater improvements than placebo in patients with skin-predominant dermatomyositis — some of it ...

The researchers concluded that brepocitinib 30 mg can provide rapid, sustained and remission-level control of cutaneous ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Rash (75.7%) and weakness (58.4%) were the most common objective flare manifestations, with pulmonary worsening (19.0%) and inflammatory arthritis (12.4%) less frequent. Patient-reported rash and ...

NEW ORLEANS — A monoclonal antibody targeting interferon beta (IFN-beta) provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase ...

Classic DM (CDM) presents with pathognomonic cutaneous findings and progressive, symmetric proximal muscle weakness. Cutaneous disease usually precedes the appearance of myositis by 3–6 months in ...

Please provide your email address to receive an email when new articles are posted on . The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent ...

LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune ...

Dermatomyositis is a rare muscle disease that causes inflammation of the muscles, skin, and blood vessels. It may also affect other organs, such as the heart and lungs. Dermatomyositis belongs to a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...